Cargando…
Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO
Objective Severe cases of coronavirus disease 2019 (COVID-19) can require continuous renal replacement therapy (CRRT) and/or extracorporeal membrane oxygenation (ECMO). Unfractionated heparin (UFH) to prevent circuit clotting is mandatory but monitoring is complicated by (pseudo)-heparin resistance...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Georg Thieme Verlag KG
2020
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676995/ https://www.ncbi.nlm.nih.gov/pubmed/33235946 http://dx.doi.org/10.1055/s-0040-1719083 |
_version_ | 1783611889924702208 |
---|---|
author | Streng, Alexander S. Delnoij, Thijs S.R. Mulder, Mark M.G. Sels, Jan Willem E.M. Wetzels, Rick J.H. Verhezen, Paul W.M. Olie, Renske H. Kooman, Jeroen P. van Kuijk, Sander M.J. Brandts, Lloyd ten Cate, Hugo Lorusso, Roberto van der Horst, Iwan C.C. van Bussel, Bas C.T. Henskens, Yvonne M.C. |
author_facet | Streng, Alexander S. Delnoij, Thijs S.R. Mulder, Mark M.G. Sels, Jan Willem E.M. Wetzels, Rick J.H. Verhezen, Paul W.M. Olie, Renske H. Kooman, Jeroen P. van Kuijk, Sander M.J. Brandts, Lloyd ten Cate, Hugo Lorusso, Roberto van der Horst, Iwan C.C. van Bussel, Bas C.T. Henskens, Yvonne M.C. |
author_sort | Streng, Alexander S. |
collection | PubMed |
description | Objective Severe cases of coronavirus disease 2019 (COVID-19) can require continuous renal replacement therapy (CRRT) and/or extracorporeal membrane oxygenation (ECMO). Unfractionated heparin (UFH) to prevent circuit clotting is mandatory but monitoring is complicated by (pseudo)-heparin resistance. In this observational study, we compared two different activated partial thromboplastin time (aPTT) assays and a chromogenic anti-Xa assay in COVID-19 patients on CRRT or ECMO in relation to their UFH dosages and acute phase reactants. Materials and Methods The aPTT (optical [aPTT-CS] and/or mechanical [aPTT-STA] clot detection methods were used), anti-Xa, factor VIII (FVIII), antithrombin III (ATIII), and fibrinogen were measured in 342 samples from 7 COVID-19 patients on CRRT or ECMO during their UFH treatment. Dosage of UFH was primarily based on the aPTT-CS with a heparin therapeutic range (HTR) of 50–80s. Associations between different variables were made using linear regression and Bland–Altman analysis. Results Dosage of UFH was above 35,000IU/24 hours in all patients. aPTT-CS and aPTT-STA were predominantly within the HTR. Anti-Xa was predominantly above the HTR (0.3–0.7 IU/mL) and ATIII concentration was >70% for all patients; mean FVIII and fibrinogen were 606% and 7.5 g/L, respectively. aPTT-CS correlated with aPTT-STA ( r (2) = 0.68) with a bias of 39.3%. Correlation between aPTT and anti-Xa was better for aPTT-CS (0.78 ≤ r (2) ≤ 0.94) than for aPTT-STA (0.34 ≤ r (2) ≤ 0.81). There was no general correlation between the aPTT-CS and ATIII, FVIII, fibrinogen, thrombocytes, C-reactive protein, or ferritin. Conclusion All included COVID-19 patients on CRRT or ECMO conformed to the definition of heparin resistance. A patient-specific association was found between aPTT and anti-Xa. This association could not be explained by FVIII or fibrinogen. |
format | Online Article Text |
id | pubmed-7676995 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Georg Thieme Verlag KG |
record_format | MEDLINE/PubMed |
spelling | pubmed-76769952020-11-23 Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO Streng, Alexander S. Delnoij, Thijs S.R. Mulder, Mark M.G. Sels, Jan Willem E.M. Wetzels, Rick J.H. Verhezen, Paul W.M. Olie, Renske H. Kooman, Jeroen P. van Kuijk, Sander M.J. Brandts, Lloyd ten Cate, Hugo Lorusso, Roberto van der Horst, Iwan C.C. van Bussel, Bas C.T. Henskens, Yvonne M.C. TH Open Objective Severe cases of coronavirus disease 2019 (COVID-19) can require continuous renal replacement therapy (CRRT) and/or extracorporeal membrane oxygenation (ECMO). Unfractionated heparin (UFH) to prevent circuit clotting is mandatory but monitoring is complicated by (pseudo)-heparin resistance. In this observational study, we compared two different activated partial thromboplastin time (aPTT) assays and a chromogenic anti-Xa assay in COVID-19 patients on CRRT or ECMO in relation to their UFH dosages and acute phase reactants. Materials and Methods The aPTT (optical [aPTT-CS] and/or mechanical [aPTT-STA] clot detection methods were used), anti-Xa, factor VIII (FVIII), antithrombin III (ATIII), and fibrinogen were measured in 342 samples from 7 COVID-19 patients on CRRT or ECMO during their UFH treatment. Dosage of UFH was primarily based on the aPTT-CS with a heparin therapeutic range (HTR) of 50–80s. Associations between different variables were made using linear regression and Bland–Altman analysis. Results Dosage of UFH was above 35,000IU/24 hours in all patients. aPTT-CS and aPTT-STA were predominantly within the HTR. Anti-Xa was predominantly above the HTR (0.3–0.7 IU/mL) and ATIII concentration was >70% for all patients; mean FVIII and fibrinogen were 606% and 7.5 g/L, respectively. aPTT-CS correlated with aPTT-STA ( r (2) = 0.68) with a bias of 39.3%. Correlation between aPTT and anti-Xa was better for aPTT-CS (0.78 ≤ r (2) ≤ 0.94) than for aPTT-STA (0.34 ≤ r (2) ≤ 0.81). There was no general correlation between the aPTT-CS and ATIII, FVIII, fibrinogen, thrombocytes, C-reactive protein, or ferritin. Conclusion All included COVID-19 patients on CRRT or ECMO conformed to the definition of heparin resistance. A patient-specific association was found between aPTT and anti-Xa. This association could not be explained by FVIII or fibrinogen. Georg Thieme Verlag KG 2020-11-19 /pmc/articles/PMC7676995/ /pubmed/33235946 http://dx.doi.org/10.1055/s-0040-1719083 Text en The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. ( https://creativecommons.org/licenses/by/4.0/ ) https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Streng, Alexander S. Delnoij, Thijs S.R. Mulder, Mark M.G. Sels, Jan Willem E.M. Wetzels, Rick J.H. Verhezen, Paul W.M. Olie, Renske H. Kooman, Jeroen P. van Kuijk, Sander M.J. Brandts, Lloyd ten Cate, Hugo Lorusso, Roberto van der Horst, Iwan C.C. van Bussel, Bas C.T. Henskens, Yvonne M.C. Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO |
title | Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO |
title_full | Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO |
title_fullStr | Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO |
title_full_unstemmed | Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO |
title_short | Monitoring of Unfractionated Heparin in Severe COVID-19: An Observational Study of Patients on CRRT and ECMO |
title_sort | monitoring of unfractionated heparin in severe covid-19: an observational study of patients on crrt and ecmo |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7676995/ https://www.ncbi.nlm.nih.gov/pubmed/33235946 http://dx.doi.org/10.1055/s-0040-1719083 |
work_keys_str_mv | AT strengalexanders monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT delnoijthijssr monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT muldermarkmg monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT selsjanwillemem monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT wetzelsrickjh monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT verhezenpaulwm monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT olierenskeh monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT koomanjeroenp monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT vankuijksandermj monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT brandtslloyd monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT tencatehugo monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT lorussoroberto monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT vanderhorstiwancc monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT vanbusselbasct monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo AT henskensyvonnemc monitoringofunfractionatedheparininseverecovid19anobservationalstudyofpatientsoncrrtandecmo |